Avivagen Announces Results From Its Annual General Meeting April 10, 2019

Avivagen Inc. (TSXV:VIV) (Avivagen or the Corporation), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces that at the Corporations Annual General Meeting (AGM) held yesterday the Corporations shareholders voted to support all of the resolutions that came before the meeting. The resolutions included the reappointment of UHY McGovern Hurley LLP as Avivagens auditor and the election of directors.

The voting results in respect of the election of directors are detailed below:

Nominee  

% Of Votes Cast At The Meeting Which Were Cast for the Election of Directors

     

% Of Votes Cast At The Meeting Which Were Withheld From Voting

Kym Anthony 99.0% 1.0%
Graham Burton 99.0% 1.0%
Aubrey Dan 99.3% 0.7%
David Hankinson 99.0% 1.0%
Jeffrey Kraws 99.3% 0.7%
Paul Mesburis 99.3% 0.7%

About Avivagen Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

About OxC-beta„¢ Technology and OxC-beta„¢ Livestock Avivagens OxC-beta„¢ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta„¢ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta„¢ Livestock is currently registered and available for sale in the United States, Philippines, Taiwan, New Zealand and Thailand.

Avivagens OxC-beta„¢ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta„¢ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Vivamune„¢ Health Chews (Vivamune„¢) Vivamune„¢ is an all-in-one chew that can dramatically simplify a pets supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta„¢, Vivamune„¢ targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune„¢ is available for sale in the United States, Canada, Philippines, Taiwan and New Zealand. For more information, visit www.vivamunehealth.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim, anticipate, appear, believe, consider, could, estimate, expect, if, intend, goal, hope, likely, may, plan, possibly, potentially, pursue, seem, should, whether, will, would and similar expressions. Statements regarding the potential for OxC-beta„¢ Livestock to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds due to many factors, many of which are outside of Avivagens control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright 2019 Avivagen Inc. OxC-beta„¢ is a trademark of Avivagen Inc.

Avivagen Inc.
Drew Basek
Director of Investor Relations
100
Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail:
[email protected]

Kym Anthony
Interim Chief Executive Officer
100 Sussex Drive,
Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website:
www.avivagen.com